To provide guidance on optimal bridging therapy (BT) before anti-BCMA CAR-T therapy for heavily pretreated patients in the European multiple myeloma community, targeting healthcare professionals involved in treatment decisions.
Key Findings:
Effective BT can enhance efficacy and safety outcomes of anti-BCMA CAR-T therapy.
BT should aim to reduce tumor burden and maintain or improve patient performance status.
Patient characteristics are crucial for selecting appropriate BT, especially in difficult-to-treat populations.
Talquetamab, a bispecific T-cell engager, shows promise as a BT option based on expert experience and clinical trials.
Interpretation:
The consensus emphasizes the importance of tailored BT strategies to optimize patient outcomes in the context of anti-BCMA CAR-T therapy, particularly for those with heavy pretreatment histories, linking specific strategies to improved efficacy.
Limitations:
The consensus is based on expert opinion and may not reflect all clinical scenarios, particularly in diverse healthcare settings.
Variability in BT practices and limited data on novel therapies in later lines of treatment highlight the need for further research.
Conclusion:
This expert consensus aims to standardize care and improve clinical decision-making regarding BT in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy, addressing the evolving treatment landscape.
by Leo Rasche, Maria Theresa Krauth, Hermine Agis, Christoph Renner, Irene Strassl, Raphael Teipel, Vladan Vučinić, Katja Weisel, Wolfgang Willenbacher, Marc S. Raab
